Thromb Haemost 2015; 114(01): 198-205
DOI: 10.1160/TH15-03-0192
DOI: 10.1160/TH15-03-0192
Trial Protocol Design Paper
Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran
Authors
-
Charles V. Pollack Jr.
1 Pennsylvania Hospital, Philadelphia, Pennsylvania, USA -
Paul A. Reilly
2 Boehringer Ingelheim Pharmaceuticals, Ridgefield, Conneticut, USA -
Richard Bernstein
3 Northwestern University, Chicago, Illinois, USA -
Robert Dubiel
2 Boehringer Ingelheim Pharmaceuticals, Ridgefield, Conneticut, USA -
John Eikelboom
4 McMaster University, Hamilton, Ontario, Canada -
Stephan Glund
5 Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany -
Menno V. Huisman
6 Leiden University Medical Center, Leiden, Netherlands -
Elaine Hylek
7 Boston University School of Medicine, Boston, Massachusetts, USA -
Chak-Wah Kam
8 Tuen Mun Hospital, Tuen Mun, NT, Hong Kong -
Pieter W. Kamphuisen
9 University Medical Center, Groningen, Netherlands -
Joerg Kreuzer
10 Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany -
Jerrold H. Levy
11 Duke University Medical Center, Durham, North Carolina, USA -
Frank Sellke
12 Brown Medical School, Providence, Rhode Island, USA -
Joachim Stangier
5 Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany -
Thorsten Steiner
13 University of Heidelberg, Heidelberg, Germany -
Bushi Wang
2 Boehringer Ingelheim Pharmaceuticals, Ridgefield, Conneticut, USA -
Jeffrey I. Weitz
4 McMaster University, Hamilton, Ontario, Canada